Welcome to On-line version of the Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2023.  The content represents the most up-to-date information on the diagnosis and treatment of viral hepatitis mad chronic liver disease. Your faculty are leading hepatologists from across the country.

The educational content resides on our digital app and you will be provided log-on information and credentials. When you have completed the course work, you will be directed to a site to take the required CME quiz, evaluate the seminar, and request your Continuing Education credits.

Target Audience
Gastroenterologists, Internists, Hepatologists, family physicians, clinical pharmacists as well as related advanced-practice clinicians and nurse specialists. 

Joint Provider Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and SC Liver Research Consortiun. The University of Louisville is accredited by the ACCME to provide continuing education for physicians.


Designation Statement
The University of Louisville Office of Continuing Medical Education & Professional Development designates this enduring material for a maximum of 10.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1317. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content. Completion criteria to obtain CE's: Attend entire session and complete the evaluation.

Course Instructions 
This online CME activity has been developed by the University of Louisville School of Medicine in joint providership with SC Liver Research Consortia. During the course you will watch and listen to a series of 16 video presentations. You will have to register and create a user profile before you are able to download the digital app and view the video material. Once the material has been viewed, you will take a brief post-activity test followed by a course evaluation, after which you will be able to generate your CME/CE certificate.

Accreditation Disclosure
As a provider accredited by the ACCME, the Office of CME&PD, School of Medicine, University of Louisville, must ensure balance, independence, objectivity, and scientific rigor in all its accredited educational activities. All Planners, faculty, reviewers, and other persons that affected the content of this CME activity were required to submit a financial disclosure form from which relevant conflicts of interest were determined. If any relevant financial relationship(s) with ineligible companies were disclosed, the materials each of them prepared for this program (or influenced) were peer-reviewed and determined to be without ineligible company bias, were considered fair and balanced in terms of therapeutic options, and presented evidence-based content. All relevant financial relationships with ineligible organizations have been mitigated prior to this activity.

Paul Pockros, MD - Course Director, Planner, Faculty; Speaking Fees: Intercept, Gilead, AbbVie, Durect; Consulting Fees: AbbVie, GSK, Gilead, Intercept, Altimmune, Boston Pharmaceuticals, Antios Therapeutics, f5 Therapeutics; Contracted Research: Intercept, Gilead, Chemomab; Stock Dividends: f5 Therapeutics, Novo.
Howard J, Horwitz, MPH - Course Coordinator, Planner; has no relevant financial relationships to disclose.
Kirti Shetty, MD - Planner, Faculty; Contracted Research Funding: Glycotest, HANMI-TRIA, Durect, Ocera-Biolet, Glocogen.
Hugo Vargas, MD - Planner; Consulting Fees: Malllinckrodt.
Julio Gutierrez, MD - Faculty; Speaking Fees: Abbvie, Gilead; Consulting Fees: AbbVie, Gilead.
Tse-Ling Fong, MD - Faculty; Contracted Research Funding: Gilead.
Paul Martin, MD - Faculty; Consulting Fees: AbbVie, Theratechnologies; Contracted Research Funding: Genfit, Durect, Girfols, Sera Trials, Target, Viking, Enanta.
Craig McClain, MD - Faculty; Consulting Fees: Intercept; Contracted Research Funding: NIH, VAMC, Target Pharma Solutions.
Ashutosh Barve, MD, PhD - Faculty; Speaking Fees: Elexis; Consulting Fees: Elexis.
Andrew Muir, MD - Faculty; Consulting Fees: Abbvie, Gilead; Grant Funding: Gilead.
Lisa Forman, MD -  Faculty; Contracted Research Funding: Gilead,  Mirum, Intercept, Cymabay.
Sidney Barritt, MD - Faculty; Consulting Fees: Target RWE, Pfizer, Protagonist; Writing Support Fees: Novo Nordisk
Robert Gish, MD - Faculty; Speaking Fees: AbbVie, BMS, Eisai, Genentech, Gilead Sciences, Intercept; Consulting Fees: Abbott, AbbVie, Altimunne, Antios, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Janssen, Helios, Merck, Pfizer, Venatorx; Stocks/Stock Option Dividends: RiboSciences, CoCrystal; Advisory Boards Payment: AbbVie, Antios, Eiger, Enyo, Gilead, HepQuant, Intercept, Janssen, Merck, Prodigy.
Soon Bahrami, MD - Content Reviewer; has no relevant financial relationships to disclose.
Tracy Ander, DO - Content Reviewer; has no relevant financial relationships to disclose. 
The University of Louisville CME & PD Advisory Board and Office Staff have nothing to disclose with the following Board Member exceptions: Sathya Krishnasamy, MD -  Novo Nordisk, Kowa (Grant Funding);  Ashlee Bergin, MD – Oraganon (Speaking Fees);  Michael Sowell, MD – Amgen, Abbvie, Biohaven, Teva, Lundbeck (Speaking fees); Rainer Lenhardt, MD - CSL, Behring (Speaking Fees).

Hardware & Software Requirements
High speed internet connection
Browser: Google Chrome is recommended

Original Release & Termination Dates
Course Originally Released On: 2/24/2023
Date of Most Recent Review: 2/2/2023
Course Termination Date: 2/24/2025

Special Services
If you need special accommodations due to a disability, or for an alternative form of course materials, please contact Howard Horwitz. Continuing Medical Education & Professional Development fully complies with the legal requirements of the ADA and the rules and regulations thereof.

Provider Contact Information
If you need technical support or have questions about the course, please e-mail us at cmepd@louisville.edu

Privacy Policy Learner Consent Statement
The University of Louisville's Continuing Medical Education and Professional Development office respects your privacy. Personal information collected from participants of our medical educational activities will not, unless required by law, be shared with any third party. The primary reason we collect your personal information is for accountability and documentation of your continuing education activities in compliance with Accreditation Council for Continuing Medical Education (ACCME) regulations. We do not distribute unsolicited e-mails, nor, unless required by law, do we share the names of our subscribers with any third party. Names or contact information of learners will not be shared with any ineligible company or its agents without the explicit consent of the individual learner.

Copyright
The University of Louisville has obtained permission to use the content in this educational activity.

Disclosure of Support from Ineligible Companies
This Internet Activity Enduring Material is Supported by educational grants from AbbVie, Exelixis, Gilead, Madrigal, Mallinckrodt.

Course Learning Objectives
As a result of participating in this activity, participants should be able to:
1. Review the history, epidemiology, demographics, natural history, immunology, and pathophysiology that leads to increased incidence of viral hepatitis.
2. Explore the factors that have led to a resurgence of Hepatitis A and the diagnostic and treatment guidelines for Delta Hepatitis and Hepatitis E.
3. Formulate and/or implement strategies for preventing, diagnosing, treating, and/or referring patients with viral hepatitis.
4. Review the current therapies for PBC and clinical approaches for PSC.
5. Incorporate new and emerging treatment regimes for PBC from the latest EASL and AASLD presented papers.
6. Evaluate the short and long-term health concerns brought on by SARS-CoV-2.
7. Summarize the causes of chronic liver disease and hepatic encephalopathy and promising treatments.
8. Explore the causes and impact of alcohol on liver wellbeing and progressive liver disease.
9. Perform the appropriate diagnostic tests required to ensure early diagnosis of hepatocellular carcinoma (HCC).
10. Integrate newer treatment options for HCC as well as approaches to reduce tumor size and number.
11. Examine treatment options for thrombocytopenia, including therapeutic alternatives to platelet transfusion.
12. Discover the pathway and barriers to liver disease elimination and the unique challenges of special populations.
13. Employ the progression pathways of Fatty Liver Disease to NASH to Liver Cancer to improve patient management.
14. Utilize current clinical cases to improve diagnostic and treatment skills.
15. Improve the health of patients infected with hepatitis virus, liver cancer and other progressive liver diseases.

Registration

Fees
1. Physicians and Clinical Pharmacists - $95
2. Nurses, Nurse Practitioners and PAs - $70
3. Medical Residents & Fellows - $50
4. All Others - $95

TO REGISTER AND BEGIN THE COURSE   CLICK HERE
After you complete your registration,  an email confirmation will be sent. It has a "Click Here for App instructions" link leading to instructions on how to download the digital app and view the presentation material. Be sure to save the email and password you developed when you registered and paid for this course. After watching all the presentations, you will have to login again to complete the post-test, evaluation, and generate your Continuing Education certificate.

Content Questions and Comments
All participants are invited to submit their questions or comments about the content or cases in the presentations to cme@scliver.com
Questions will be routed one of the faculty experts for reply and each will be answered within 48 hours of receipt.

Attendee Cancellation, Substitution, Refund Policy
The course tuition is refundable, minus a $20 processing fee, if your cancellation is received prior to accessing the course content in the digital app. No refunds or credits will be given after the course materials are accessed.